Oncoceutics - Ownership and Business Overview

Life ScienceCompany

Oncoceutics Ownership

Who owns Oncoceutics?

Oncoceutics is owned by Chimerix. It was acquired on January 8, 2021.

Was Oncoceutics formerly PE-backed?

Yes. Oncoceutics was formerly owned by 1 private investor.

Oncoceutics Business Overview

Where is Oncoceutics headquartered?

Oncoceutics is headquartered in Philadelphia, Pennsylvania.

What sector is Oncoceutics in?

Oncoceutics is a life science company.

When was Oncoceutics founded?

Oncoceutics was founded in 2009.

Life Science M&A Summary in 2021

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2021. The largest life science acquisition in 2021 was Pharmaceutical Product Development - which was acquired by Thermo Fisher Scientific for $17.4B.

Join Mergr to view all 397 acquisitions of life science companies in 2021, including 46 acquisitions by private equity firms, and 351 by strategics.

Oncoceutics, Inc.

3675 Market Street, Suite 200,
Philadelphia, Pennsylvania 19104
United States,
www.oncoceutics.com

Oncoceutics, Inc. is a clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead product candidate, ONC201, has been shown in clinical testing to selectively induce cell death in multiple cancer types. ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected in 2021. Oncoceutics, Inc. was founded in 2009 and is based in Philadelphia, Pennsylvania.


 Subscribe to unlock this and 208,718
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 204K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.